Merck KGaA Boosted By Bavencio, Mavenclad And COVID Vaccine Fees
Healthy Q3 For 'Big Three'
Executive Summary
The German group's efforts in helping its peers in the industry with their respective COVID-19 vaccines have been rewarded with strong revenue growth while its own newer drugs beat analyst forecasts.